Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma, with or without peritoneal metastases: a post-hoc analysis on RATIONALE-305 study.
Saved in:
| Title: | Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma, with or without peritoneal metastases: a post-hoc analysis on RATIONALE-305 study. |
|---|---|
| Authors: | Qiu MZ; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China., Lee KW; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea., Möhler M; Division of Hematology/Oncology, Mayo Clinic Comprehensive Cancer Center, Phoenix, AZ, USA., Luo HY; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China., Hirano H; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Zhang T; Cancer Center, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Wang FH; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China., Ba Y; Cancer Center, Peking Union Medical College Hospital, Beijing, China.; Department of GI Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China., Rha SY; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Wang F; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China., He MM; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China., Xu S; Global Statistics and Data Science, BeOne Medicines (Shanghai) Co, Ltd, Shanghai, China., Pan X; BeOne Medicines (Beijing) Co., Ltd., Beijing, China., Xu RH; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China.; Research Unit of Precision Diagnosis and treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China. |
| Source: | EClinicalMedicine [EClinicalMedicine] 2026 May 15; Vol. 95, pp. 103980. Date of Electronic Publication: 2026 May 15 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: The Lancet Country of Publication: England NLM ID: 101733727 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-5370 (Electronic) Linking ISSN: 25895370 NLM ISO Abbreviation: EClinicalMedicine Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
